Dr. John P. Leonard discusses his phase 3 multicenter study at the ASH Annual Meeting, which found that dose-adjusted R-EPOCH chemotherapy did not appear superior to standard chemoimmunotherapy for the treatment of patients with diffuse large B-cell lymphoma.